Figure 2.
Levels of plasma ETP decreased with a combination therapy of RASi and SGLT2is compared to RASi monotherapy. Longitudinal plasma endotrophin (ETP) levels stratified by treatment group over time (p for slope difference = 0.002). RASi: renin–angiotensin system inhibitor; SGLT2i: sodium–glucose co-transporter 2 inhibitor.